|
|
vii | |
Preface |
|
xi | |
|
Immunoallergic syndromes in interventional cardiology |
|
|
1 | (8) |
|
Chourmouzios A Arampatzis |
|
|
|
|
The kidney and percutaneous coronary interventions |
|
|
9 | (18) |
|
|
|
|
Treatment of coronary artery disease in diabetic patients |
|
|
27 | (12) |
|
|
|
Ad hoc percutaneous coronary intervention |
|
|
39 | (10) |
|
|
|
|
Dilemmas in non-ST elevation acute coronary syndromes |
|
|
49 | (16) |
|
|
|
|
Patients with impaired hemostasis requiring cardiac catheterization and coronary intervention |
|
|
65 | (12) |
|
|
|
|
ST elevation acute myocardial infarction admitted in a distant location |
|
|
77 | (10) |
|
|
|
|
Stable obstructive coronary disease and very low left ventricular function |
|
|
87 | (8) |
|
Pedro de Araujo Goncalves |
|
|
|
Multivessel disease in patients with acute myocardial infarction and high-risk unstable angina: culprit versus non-culprit intervention |
|
|
95 | (16) |
|
|
|
Patients requiring cardiac and non-cardiac surgical procedures following percutaneous coronary interventions |
|
|
111 | (12) |
|
|
|
Invasive treatment (percutaneous coronary intervention) of patients at high surgical risk |
|
|
123 | (12) |
|
|
Percutaneous coronary intervention for patients with multivessel disease |
|
|
135 | (18) |
|
|
|
Highly complex anatomical morphologies: percutaneous intervention versus bypass surgery |
|
|
153 | (10) |
|
|
|
Advanced atherosclerotic diseases in multiple vascular bed sites |
|
|
163 | (22) |
|
|
|
The intermediate coronary lesion |
|
|
185 | (12) |
|
|
|
Percutaneous coronary intervention in the treatment of cardiogenic shock complicating acute myocardial infarction |
|
|
197 | (6) |
|
|
|
|
|
The hypotensive patient after angioplasty: occult life-threatening percutaneous coronary intervention-related complications |
|
|
203 | (10) |
|
|
|
|
Percutaneous treatment for patients with end-stage aortic valve disease |
|
|
213 | (12) |
|
|
|
Acute coronary dissection, occlusion, and perforation during percutaneous coronary intervention: surgical, percutaneous, or medical management |
|
|
225 | (8) |
|
|
|
Septal ablation for hypertrophic cardiomyopathy: to whom, when, and how? |
|
|
233 | (10) |
|
|
|
|
|
End-stage left ventricular failure: potential catheter-based therapeutic strategies |
|
|
243 | (10) |
|
|
|
|
Massive pulmonary embolism: the potential of catheter-based strategies |
|
|
253 | (8) |
|
|
Large thrombus burden, slow-flow, no-reflow, and distal embolization |
|
|
261 | (22) |
|
|
|
The role of interventional cardiology in functional coronary stenosis |
|
|
283 | (10) |
|
|
|
|
|
Complications of drug-eluting stents: thrombosis and restenosis |
|
|
293 | (12) |
|
|
|
Coronary interventions in patients with antiplatelet therapy resistance |
|
|
305 | (16) |
|
|
Index |
|
321 | |